Ligand Pharmaceuticals (LGND) Is Up 8.1% After Swinging to Profit and Filing New Equity Shelf – What’s Changed

• In late February 2026, Ligand Pharmaceuticals reported a sharp improvement in fourth-quarter and full-year 2025 results, turning prior-year losses into net income of US$44.78 million for the quarter and US$124.45 million for the year, while reiterating 2026 revenue guidance of US$245 million to US$285 million.
• At the same time, the company moved to broaden its financing and capital-raising options by filing a US$100 million at-the-market common stock offering and an omnibus shelf registration covering common and preferred stock, debt securities, warrants and units.
• With this combination of stronger earnings and fresh capital flexibility, we’ll now examine how the news reshapes Ligand’s investment narrative.

Find 49 companies with promising cash flow potential yet trading below their fair value.

Ligand Pharmaceuticals Investment Narrative Recap

To own Ligand today, you need to believe its asset light royalty model can keep translating partner drug progress into sustained cash generation, while managing concentrated product risk. The latest earnings rebound and reaffirmed 2026 guidance support confidence in near term royalty momentum, but the new US$100 million at the market program introduces incremental dilution risk that does not materially change the core catalyst around partner execution on key launches.

The omnibus shelf registration filed alongside the at the market equity program is particularly relevant here, as it enlarges Ligand’s toolkit to fund acquisitions and external asset deals that expand its royalty base. For investors focused on upcoming product and royalty milestones, this broader financing capacity sits in the background, potentially enabling the company to lean further into the same acquisition driven model that underpins its current catalyst story.

Yet beneath the stronger earnings and added capital flexibility, investors should still be aware of concentrated exposure to a handful of royalty assets such as…

Read the full narrative on Ligand Pharmaceuticals (it’s free!)

Ligand Pharmaceuticals’ narrative projects $315.6 million revenue and $121.1 million earnings by 2028. This requires 18.9% yearly revenue growth and a $197.0 million earnings increase from -$75.9 million today.

Uncover how Ligand Pharmaceuticals’ forecasts yield a $243.44 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span a wide range between US$38.77 and US$279.18, underlining how far apart individual views can be. When you set those against the reliance on a concentrated royalty portfolio, it becomes even more important to compare several viewpoints before deciding how Ligand’s story fits into your own expectations.

Explore 3 other fair value estimates on Ligand Pharmaceuticals – why the stock might be worth less than half the current price!

The Verdict Is Yours

Don’t just follow the ticker – dig into the data and build a conviction that’s truly your own.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don’t delay:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com